Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS Debt-to-Equity Related Terms
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS Debt-to-Equity Chart
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS Debt-to-Equity vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS (IST:ECILC) has a Debt-to-Equity of 0.06 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS and its competitors. This is 50% above median its historical median of 0.04. Over the past decade, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's Debt-to-Equity has ranged from 0.01 to 0.15. According to the industry distribution chart, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS ranks #158 out of 813 companies in the Drug Manufacturers industry, placing it in the top 19.4%.
Is EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's Debt-to-Equity too high?
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's current Debt-to-Equity of 0.06 is 50% above median its 10-year median of 0.04. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.15. The Drug Manufacturers industry median Debt-to-Equity is 0.27. EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's value of 0.06 is 77.8% below this industry median. Based on the distribution chart, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS ranks #158 out of 813 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS ranks #158 out of 813 companies for Debt-to-Equity. This places EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS in the top 19% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.27. EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's value of 0.06 is 77.8% below this benchmark. Historically, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's own Debt-to-Equity has ranged from 0.01 to 0.15 over the past decade. While the company's 10-year median is 0.04 vs. the industry median of 0.27, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's current Debt-to-Equity of 0.06 is 77.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's current Debt-to-Equity is 0.06, which is 50% above median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS (IST:ECILC) is currently considered Modestly Overvalued. The stock's GF Value™ is ₺61.11, compared to a current price of ₺73.50 — trading 20.3% above its estimated fair value. The current Debt-to-Equity is 0.06, which is 50% above median its 10-year median of 0.04 and 77.8% below the Drug Manufacturers industry median of 0.27. EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS (IST:ECILC), the current Debt-to-Equity is 0.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS (IST:ECILC) Overvalued in 2026?
Based on GuruFocus' analysis, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS stock appears to be overvalued.
The current stock price of ₺73.50 is trading 20.3% above its estimated GF Value™ of ₺61.11.
GuruFocus considers EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS to be Modestly Overvalued.
Key valuation signals for IST:ECILC:
Debt-to-Equity: 0.06 (50% above median its 10-year median of 0.04)
GF Value™: ₺61.11 vs. price of ₺73.50 (20.3% above fair value)
Industry Position: 77.8% below the Drug Manufacturers median (#158 of 813)
No single metric tells the full story. See the IST:ECILC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS Business Description
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS is a Turkey-based company that operates in the drug business. It is mainly involved in the manufacturing of pharmaceuticals, veterinary drugs, and personal care products. Further, the group is also engaged in real estate development and leasing commercial property activities. Geographically, all the activities are carried out through the region of Turkey.
63GF Score
Get the complete analysis for IST:ECILC
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:ECILC has been successfully added to your 
